These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11441408)

  • 1. New drug and multimodality combinations in the treatment of advanced non--small cell lung cancer.
    Kawahara M; Kris MG; Green M; Kunitoh H
    Semin Oncol; 2001 Jun; 28(3 Suppl 9):1-4. PubMed ID: 11441408
    [No Abstract]   [Full Text] [Related]  

  • 2. Docetaxel combination produces 2-year survival advantage in NSCLC patients.
    Oncology (Williston Park); 2001 Dec; 15(12):1559, 1564. PubMed ID: 11780700
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
    Postmus P
    Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S48-50. PubMed ID: 12538936
    [No Abstract]   [Full Text] [Related]  

  • 4. New approaches in the adjuvant and neoadjuvant therapy of non-small cell lung cancer, including docetaxel (Taxotere) combinations.
    Rosell R
    Semin Oncol; 1999 Jun; 26(3 Suppl 11):32-7. PubMed ID: 10458209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of docetaxel (Taxotere) in non-small cell lung cancer.
    Kris MG; Miller VA; Ng KK; Grant SC
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-1-S14-4. PubMed ID: 9335515
    [No Abstract]   [Full Text] [Related]  

  • 6. Docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
    Kris MG; Millward M
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):1-2. PubMed ID: 10437742
    [No Abstract]   [Full Text] [Related]  

  • 7. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy for non-small cell lung cancer: is more better or just simply more?
    Shepherd FA
    Lung Cancer; 2002 Jun; 36(3):309-11. PubMed ID: 12009243
    [No Abstract]   [Full Text] [Related]  

  • 9. Study shows 2-year survival advantage for docetaxel.
    Expert Rev Anticancer Ther; 2001 Oct; 1(3):323-4. PubMed ID: 12113094
    [No Abstract]   [Full Text] [Related]  

  • 10. Docetaxel in the management of advanced non-small cell lung cancer.
    Miller VA
    Semin Oncol; 1998 Jun; 25(3 Suppl 8):15-9. PubMed ID: 9704671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trials of vinorelbine and docetaxel in the treatment of advanced non-small cell lung cancer.
    Krug LM; Miller VA
    Semin Oncol; 1999 Oct; 26(5 Suppl 16):24-6; discussion 41-2. PubMed ID: 10585005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
    Harper P
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel (Taxotere) and neoadjuvant chemotherapy for non-small cell lung cancer.
    Mattson K
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):25-8. PubMed ID: 10437748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel (Taxotere) in combination with platinum-based regimens in non-small cell lung cancer: results and future developments.
    Belani CP
    Semin Oncol; 1999 Jun; 26(3 Suppl 10):15-8. PubMed ID: 10437746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC; Hsu Schmitz SF; Tötsch M; Hansen E; Joss C; von Briel C; Schmid RA; Pless M; Habicht J; Roth AD; Spiliopoulos A; Stahel R; Weder W; Stupp R; Egli F; Furrer M; Honegger H; Wernli M; Cerny T; Ris HB
    J Clin Oncol; 2003 May; 21(9):1752-9. PubMed ID: 12721251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide and docetaxel in non-small cell lung cancer.
    Drings P; Büchholz E; Manegold C
    Semin Oncol; 1998 Feb; 25(1 Suppl 2):29-37. PubMed ID: 9535209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
    Aapro MS
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of docetaxel (Taxotere) in non-small cell lung cancer--docetaxel in new combinations and new schedules: an overview of ongoing and future developments.
    Donnellan PP; Crown JP
    Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-18-S14-21. PubMed ID: 9335519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The taxanes: an update.
    Crown J; O'Leary M
    Lancet; 2000 Apr; 355(9210):1176-8. PubMed ID: 10791395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.